Form 4: MaxCyte Director Stanley Erck Exercises Options and Sells Shares Under 10b5-1 Plan

Director Stanley Erck exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged 10b5-1 trading plan.

Summary

• Stanley Erck, a director of MaxCyte, Inc., executed transactions involving the company's common stock on October 1 and October 2, 2024.
• These transactions involved the exercise of employee stock options and the subsequent sale of the acquired shares.
• The exercises and sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2024.
• On October 1, 2024, Erck exercised options to acquire 26,082 shares at a price of $0.04 per share and then sold the same number of shares at a weighted average price of $3.78, resulting in 269,118 shares held.
• On October 2, 2024, Erck exercised options to acquire 21,607 shares at a price of $0.04 per share and then sold the same number of shares at a weighted average price of $3.71, resulting in 269,118 shares held.
• The options exercised are scheduled to expire on November 11, 2024.
• Following these transactions, Erck continues to beneficially own 269,118 shares of MaxCyte common stock directly and 47,689 shares indirectly through employee stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives and directors to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director selling shares, but the pre-arranged nature of the sales mitigates concerns about insider information.

Key Dates